Cybin Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mike Cola

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Feb 25

CEO

Mike Cola (65 yo)

less than a year

Görev süresi

Mr. Michael F. Cola, also known as Mike, is Chief Executive Officer of Cybin Inc. from February 10, 2026. Mr. Cola is an Independent Chairman of Phathom Pharmaceuticals, Inc. He served as Chief Executive O...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric So	Co-Founder	5.3yrs	US$6.84m	0.62% $ 2.3m
Paul Glavine	Co-Founder	no data	US$6.84m	0.56% $ 2.1m
Greg Cavers	Chief Financial Officer	5.3yrs	US$1.00m	0.038% $ 139.6k
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	5.3yrs	US$1.12m	0.077% $ 282.6k
George Tziras	Chief Business Officer	2.4yrs	US$843.49k	0.072% $ 266.6k
Michael Cola	Chief Executive Officer	less than a year	Veri yok	Veri yok
John Kanakis	Co-Founder	no data	US$1.19m	Veri yok
Aaron Bartlone	Chief Operating Officer	2.7yrs	US$764.06k	0.069% $ 252.2k
Alex Nivorozhkin	Chief Scientific Officer	5.3yrs	Veri yok	Veri yok
Lori Challenger	Chief Compliance	4.4yrs	Veri yok	Veri yok
Sara Somerset	Chief Communications Officers	no data	Veri yok	Veri yok
Douglas Sommerville	Chief Pharmaceutical Strategist	no data	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: HELP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric So	Co-Founder	5.3yrs	US$6.84m	0.62% $ 2.3m
Paul Glavine	Co-Founder	5.3yrs	US$6.84m	0.56% $ 2.1m
Theresa Firestone	Lead Independent Director	4.6yrs	US$286.56k	0.052% $ 191.5k
Mark Lawson	Independent Director	5.3yrs	US$291.77k	0.056% $ 206.0k
Grant Froese	Independent Director	5.3yrs	US$271.58k	0.060% $ 222.4k
Eric Hoskins	Independent Director	5.3yrs	US$271.58k	0.055% $ 203.1k

5.3yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HELP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/01 20:05
Gün Sonu Hisse Fiyatı	2026/02/27 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınıza dair rehberler ve Youtube'da eğitim videoları da sunuyoruz.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cybin Inc. 13 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
David Martin	Bloom Burton & Co.
Sumant Satchidanand Kulkarni	Canaccord Genuity

Cybin Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Insider recently bought US$73k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Announces George Tziras Not Standing for Re-Election

Cybin Inc., Annual General Meeting, Aug 18, 2025

Recent updates

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial of Spl026 in Major Depressive Disorder

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Inc. to Report Q2, 2026 Results on Nov 13, 2025

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. Highlights Upcoming Clinical Milestones

Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Insider recently bought US$73k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Announces George Tziras Not Standing for Re-Election

New major risk - Financial position

Cybin Inc. Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New minor risk - Shareholder dilution

No longer forecast to breakeven

Cybin Inc. announced that it expects to receive $500 million in funding from High Trail Special Situations LLC

Cybin Inc., Annual General Meeting, Aug 18, 2025

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

New minor risk - Share price stability

Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

No longer forecast to breakeven

New minor risk - Share price stability

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought US$64k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

Cybin Inc. Announces that George Tziras Joins the Board of Directors and Will Serve as Chief Business Officer

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023